News Sentiment

DERM sentiment intelligence

Journey Medical Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 42 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 6.91 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-2.5% over one week, +9.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.5% Price reacting lower
Trend fit Trend inactive 9.0% over four weeks
Fair value 24.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 33
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 7
TradingKey 5
TradingView 2
MarketBeat 2
Benzinga 2
AD HOC NEWS 1
Investing.com UK 1

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 14
Analyst action 4
Capital return 1
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 42
Stock Titan Direct company coverage

Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors

Wasatch Advisors has increased its beneficial ownership in Journey Medical Corp (DERM) to 13.3%, holding 2,858,930 shares. This information was disclosed in an Amendment No. 3 to a Schedule 13G filing. Wasatch Advisors maintains sole voting power over 2,664,647 shares and sole di

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 21:09
Source
Stock Titan
MarketBeat Direct company coverage

Journey Medical Corporation (NASDAQ:DERM) Receives Average Recommendation of "Hold" from Analysts

Journey Medical Corporation (NASDAQ:DERM) has received a "Hold" consensus recommendation from four analysts, with an average 12-month price target of $13.00. While some analysts maintain or upgraded to a "buy" rating, Weiss Ratings reaffirmed a "sell." The company recently report

Tone
Neutral 50/100
Event
Analyst action
Published
10 Jul 2026 08:10
Source
MarketBeat
AD HOC NEWS Direct company coverage

Journey Medical Corp focuses on dermatology growth. DERM stock reflects a specialized niche strategy

Journey Medical Corp (DERM) is a biopharmaceutical company specializing in prescription dermatology treatments for common skin conditions. The company's strategy focuses on a niche market, leveraging a concentrated sales infrastructure for conditions like acne and rosacea, and ai

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 15:41
Source
AD HOC NEWS
Stock Titan Direct company coverage

Journey Medical (DERM) grants 50,000 restricted stock units to director

Journey Medical Corp (DERM) director Toledano Miranda Jayne was granted 50,000 restricted stock units (RSUs) on July 1, 2026, under the company's 2015 Stock Plan. These RSUs will vest in three annual installments starting July 1, 2029, and increase Toledano's direct holdings to 1

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

Journey Medical (DERM) grants director 50,000 restricted stock units

Journey Medical Corp (DERM) director Neil Herskowitz was granted 50,000 restricted stock units (RSUs) on July 1, 2026, as part of his equity compensation under the company’s 2015 Stock Plan. These RSUs will vest in three tranches between 2029 and 2031. Following this award, Hersk

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:10
Source
Stock Titan
Investing.com UK Direct company coverage

Form 4 Journey Medical Corp For: 2 July By Investing.com

This article reports on a Form 4 filing by Journey Medical Corp for July 2nd, as reported by Investing.com. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report transactions in their company's stock. The article itself

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:10
Source
Investing.com UK
Stock Titan Direct company coverage

Journey Medical (DERM) director awarded 50,000 RSUs in long-term stock plan grant

Journey Medical Corp director Justin Adam Smith was granted 50,000 restricted stock units (RSUs) as equity compensation on July 1, 2026, under the company's 2015 Stock Plan. These RSUs will vest in three tranches between 2029 and 2031, aligning his compensation with future compan

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:09
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Journey Medical Corp For: 26 June By Investing.com

This article from Investing.com reports the filing of Form 4 for Journey Medical Corp on June 26th. It notes the stock symbol DERM and its performance (+4.27%). The content is very brief, mainly serving as an announcement of the filing without further details.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 22:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Journey Medical (DERM) 2026 meeting backs all directors and re-approves KPMG

Journey Medical Corporation held its 2026 annual stockholder meeting where 81% of eligible shares were represented, establishing a quorum. Stockholders approved the re-election of all six director nominees, each receiving over 31.7 million votes. Additionally, KPMG LLP was re-app

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Journey Medical (DERM) director awarded 10,000 restricted stock units in equity grant

Journey Medical Corp director Neil Herskowitz was granted 10,000 restricted stock units (RSUs) as equity compensation under the company's 2015 Stock Plan. These RSUs will vest in full on June 25, 2027, bringing Herskowitz's direct holdings to 118,618 shares, including other restr

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:21
Source
Stock Titan
Stock Titan Direct company coverage

Director at Journey Medical (DERM) receives 10,000 restricted stock units

Journey Medical Corp director Justin Adam Smith was granted 10,000 restricted stock units (RSUs) on June 25, 2026, which will vest on June 25, 2027. This equity award, made under the company’s 2015 Stock Plan, increases Smith's direct holdings to 181,618 shares, including other u

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:21
Source
Stock Titan
Stock Titan Direct company coverage

Journey Medical (DERM) director receives 10,000 RSUs vesting in 2027

Journey Medical Corp director Michael Cooper was granted 10,000 Restricted Stock Units (RSUs) on June 25, 2026, as per a Form 4 filing. These RSUs, awarded under the company's 2015 Stock Plan, will fully vest into 10,000 common shares on June 25, 2027. Following this grant, Coope

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:18
Source
Stock Titan
Stock Titan Direct company coverage

Journey Medical (DERM) director granted 10,000 RSUs, holds over 397K shares

Journey Medical Corp director Lindsay A. Rosenwald, M.D. was granted 10,000 restricted stock units (RSUs) on June 25, 2026, which will vest entirely on June 25, 2027. Following this award, Dr. Rosenwald directly holds 221,146 shares and indirectly holds 176,470 shares through an

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:16
Source
Stock Titan
TradingKey Direct company coverage

Journey Medical Corp (DERM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Journey Medical Corp (DERM), noting its current valuation score of 9.11, ranking 51st in the Pharmaceuticals industry. The analysis details the company's current P/E ratio, its deviation from recent highs and lows, and mentions that

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:39
Source
TradingKey
TradingKey Direct company coverage

Journey Medical Corp (DERM) Institutional Confidence

Journey Medical Corp (DERM) has an institutional shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding witnessed a significant quarter-over-quarter increase of 93.34%, with the largest shareholder, Bill Nygren, holding

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Journey Medical Corp (DERM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Journey Medical Corp (DERM) has an earnings forecast score of 8.00, placing it well within the Pharmaceuticals industry. Analysts have set an average price target of $13.00, with a consensus "Buy" rating based on four analysts. The company's expected revenue for the next quarter

Tone
Positive 68/100
Event
Earnings
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Journey Medical Corp (DERM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Journey Medical Corp (DERM), detailing its performance by business segments and regional contributions. As of April 6, the company's fiscal year 2025 revenue is dominated by Qbrexza, Emrosia, and Accutane. The entire revenue generated

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 23:10
Source
TradingKey
TradingKey Direct company coverage

Journey Medical Corp (DERM) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a financial overview of Journey Medical Corp (DERM), focusing on its dividend and stock split history. It states that the company has not distributed dividends in the past five years and has no record of stock splits. The page also displays current stock para

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 22:10
Source
TradingKey
Bez Kabli Direct company coverage

Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial

Journey Medical Corp's shares dropped 3.5% after no new company statement was released. The company's 2026 outlook is heavily dependent on the performance of its rosacea drug, Emrosi, specifically its ability to increase prescriptions, secure payer coverage, maintain margins, and

Tone
Negative 38/100
Event
Guidance
Published
02 Jun 2026 23:03
Source
Bez Kabli
Ad Hoc News Direct company coverage

Journey Medical Corp stock (US48113J1007): calm start to the week after recent gains

Journey Medical Corp (DERM) shares started the week calmly on Nasdaq after recent gains in May, maintaining its presence in the U.S. small-cap market. The commercial-stage dermatology specialist's stock traded in a mid-single-digit dollar range, attracting attention from investor

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 18:10
Source
Ad Hoc News
Investing.com Direct company coverage

Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise

Journey Medical Corporation reported a strong first quarter for 2026, with total net product revenues increasing 21% year-over-year, driven by a 200% surge in EMROSI product revenue. The company achieved positive adjusted EBITDA of $600,000 and increased its cash position to $27.

Tone
Neutral 50/100
Event
Earnings
Published
26 May 2026 11:10
Source
Investing.com
Benzinga Direct company coverage

Journey Medical Analyst Ratings and Price Targets | NASDAQ:DERM

Journey Medical Corp (NASDAQ: DERM) has a consensus price target of $11.08 from 6 analysts, with a high of $13.00 from HC Wainwright & Co. and a low of $8.50 from Alliance Global Partners. Recent ratings suggest a potential 106.02% upside for the stock. The latest analyst rating

Tone
Positive 77/100
Event
Analyst action
Published
24 May 2026 09:10
Source
Benzinga
Stock Titan Direct company coverage

Journey Medical CEO to join online talk at A.G.P. health event

Journey Medical Corporation announced that its Co-Founder, President, and CEO, Claude Maraoui, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026, at 5:00 p.m. ET. The company, focused on FDA-approved dermatological products, enco

Tone
Neutral 50/100
Event
Market update
Published
20 May 2026 19:40
Source
Stock Titan
Pluang Direct company coverage

Journey Medical CEO to join A.G.P. Virtual Healthcare Conference fireside chat on May 20, 2026

Journey Medical Corporation's CEO, Claude Maraoui, is scheduled to participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. The company specializes in dermatological prescription drugs and markets eight branded products. This event provides

Tone
Neutral 50/100
Event
Market update
Published
20 May 2026 00:39
Source
Pluang
The Manila Times Direct company coverage

Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Journey Medical Corporation (Nasdaq: DERM) announced that its Co-Founder, President, and CEO, Claude Maraoui, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, at 5:00 PM ET. The company is a commercial-stage pharmace

Tone
Positive 67/100
Event
Market update
Published
19 May 2026 20:39
Source
The Manila Times